Overview

Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese

Status:
Not yet recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
A phase 2 study to assess the efficacy of bimagrumab alone or in addition to semaglutide to assess efficacy and safety in overweight or obese men and women
Phase:
Phase 2
Details
Lead Sponsor:
Versanis Bio, Inc.
Treatments:
Antibodies, Blocking
Antibodies, Monoclonal